Menveo is supplied to providers in two vials that must be combined before administration. A CDC examination of the Vaccine Adverse Event Reporting System database for reports on Menveo between March 1, 2010, and Sept. 22, 2015, revealed 390 reports of administration of only one component of the vaccine to a total of 407 recipients.
Of the 407 recipients, 346 (85 percent) experienced no adverse event. Those who did experience adverse effects typically reported redness, fever and pain.
The CDC discovered similar administration errors with Pentacel, another vaccine packaged as separate components.
To avoid future incidents, the CDC recommends providers follow the instructions provided with Menveo, including the vaccine labeling, packaging and product insert.
More articles on vaccines:
Ethnic background a factor in patient response to flu vaccine, study suggests
Herpesvirus CMV-based vaccine provides protection against Ebola, study finds
Johns Hopkins study finds expanding vaccines would be an ‘excellent investment’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
